|
|
Article: Combination therapy with Actos improves components of diabetic dyslipidemia.
- Article from:
- Biotech Business Week
- Article date:
- May 31, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 MAY 31 - (NewsRx.com & NewsRx.net) -- Results of three studies show that the oral anti-diabetic agent Actos (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline.
These studies also showed that, in addition to increasing low-density lipoprotein (LDL) cholesterol particle size, Actos can significantly increase the size and buoyancy of HDL particles. The findings were presented at the 13th Annual Meeting and Clinical Congress of the American Association of Clinical ...